287
Participants
Start Date
April 29, 2022
Primary Completion Date
October 1, 2025
Study Completion Date
October 1, 2025
Tezepelumab
Participants will be receiving subcutaneous injection of tezepelumab.
Research Site, Valhalla
Research Site, Hollis
Research Site, Rochester
Research Site, Horseheads
Research Site, Altoona
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Upper Marlboro
Research Site, Charlottesville
Research Site, Chapel Hill
Research Site, Wilmington
Research Site, Greenville
Research Site, Mobile
Research Site, Hendersonville
Research Site, Lexington
Research Site, Toledo
Research Site, Ann Arbor
Research Site, Ypsilanti
Research Site, Saint Paul
Research Site, Chicago
Research Site, St Louis
Research Site, Omaha
Research Site, Lincoln
Research Site, New Orleans
Research Site, Oklahoma City
Research Site, McKinney
Research Site, Fort Worth
Research Site, San Antonio
Research Site, Colorado Springs
Research Site, Gilbert
Research Site, Los Angeles
Research Site, Long Beach
Research Site, Rancho Mirage
Research Site, Westminster
Research Site, Vancouver
Research Site, New Haven
Research Site, Warwick
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY